{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:42:23Z","timestamp":1768437743600,"version":"3.49.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"C","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":127,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Introduction: The prognosis of metastatic colorectal cancer (mCRC) patients receiving multiple cytotoxic agents and targeted therapies (CATT) has improved, but a complete cure by CATT is still very rare.<\/jats:p>\n                    <jats:p>Presentation of case: We report the successful treatment of ascending colon cancer complicated by peritoneal disseminations (PDs) with panitumumab (Pmab) plus mFOLFOX6 therapy. A 67-year-old male patient was diagnosed with clinical stage IV cancer of the ascending colon with PDs, and underwent ileostomy. Eighteen courses of Pmab plus mFOLFOX6 caused remarkable tumor shrinkage and the disappearance of PDs on ECT. Laparotomy revealed tumor shrinkage and scarring at the PD sites. We performed right hemicolectomy, subtotal omentectomy, and ileostomy closure as curability B surgery. Seven months later, new PDs were detected by ECT so we resumed Pmab plus mFOLFOX6 therapy. After nine courses of treatment, the target lesion had completely disappeared. After a total of 20 courses, we changed to Pmab monotherapy as maintenance therapy because there was no recurrence. Forty months after the initiation of Pmab monotherapy, there has been no oncologic progression.<\/jats:p>\n                    <jats:p>Discussion: Pmab plus mFOLFOX6 treatment resulted in a complete response for PDs, which is extremely rare for CATT.<\/jats:p>\n                    <jats:p>Conclusion: We consider that Pmab therapy should be introduced for the treatment of mCRC complicated by PDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijscr.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T14:10:33Z","timestamp":1557411033000},"page":"41-45","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Peritoneal dissemination of ascending colon cancer demonstrating relapse-free survival for 40 months with panitumumab monotherapy"],"prefix":"10.1097","volume":"59","author":[{"given":"Katsuji","family":"Tokuhara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiko","family":"Hishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20260114","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","article-title":"Metastatic colorectal cancer: current state and future directions","volume":"33","author":"Fakih","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"R2-11-20260114","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijsu.2018.10.028","article-title":"The SCARE 2018 statement: updating consensus surgical CAse REport (SCARE) guidelines","volume":"60","author":"Agha","year":"2018","journal-title":"Int. J. Surg"},{"key":"R7-11-20260114","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41416-018-0165-z","article-title":"Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analysed of the PRIME and PEAK clinical trials","volume":"119","author":"Peeters","year":"2018","journal-title":"Br. J. Cancer"},{"key":"R8-11-20260114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann. Oncol"},{"key":"R10-11-20260114","first-page":"769","article-title":"Pathological complete response to SOX plus bevacizumab for treating stage IV sigmoid colon cancer","volume":"43","author":"Ibuki","year":"2016","journal-title":"Gan Kagaku Ryoho"},{"key":"R11-11-20260114","first-page":"587","article-title":"Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases","volume":"9","author":"Suetsugu","year":"2018","journal-title":"Mol. Clin. Oncol"},{"key":"R12-11-20260114","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/codi.12647","article-title":"Does the addition of targeted biological agents to first-line chemotherapy for advanced colorectal cancer increase complete response? A systematic review and meta-analysis","volume":"16","author":"Qi","year":"2014","journal-title":"Colorectal Dis"},{"key":"R13-11-20260114","doi-asserted-by":"crossref","first-page":"390","DOI":"10.12998\/wjcc.v5.i11.390","article-title":"Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy","volume":"16","author":"Ottaiano","year":"2017","journal-title":"World J. Clin. Cases"},{"key":"R14-11-20260114","doi-asserted-by":"crossref","first-page":"e4531","DOI":"10.1097\/MD.0000000000004531","article-title":"Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: results of a registry-based cohort analysis","volume":"95","author":"Bai","year":"2016","journal-title":"Medicine (Baltimore"}],"container-title":["International Journal of Surgery Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261219302457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261219302457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01612930-201959000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:44:18Z","timestamp":1768398258000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01612930-201959000-00011"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":9,"journal-issue":{"issue":"C","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijscr.2019.05.001","relation":{},"ISSN":["2210-2612"],"issn-type":[{"value":"2210-2612","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}